Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-367-250"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-367-250"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-367-5002
lpv:speaker	lp:Françoise Castex2
lpv:spokenAs	member; CRIM (2012-03-28--2013-10-23)3 vice-chair; JURI (2012-03-01--2014-06-30)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; EMPL (2012-01-19--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 unknown; Parti socialiste (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3
lpv:translated text	"We must detect, assess and prevent the undesirable effects of medicines that are put on the market in the European Union, and we must do so at European level. Following the Mediator affair, the Commission implemented a ‘stress test’ which allowed us to identify weaknesses in current legislation. The present revisions are the result of this process. The improvements made today are numerous: most notably, the introduction of an automatic urgent procedure, the creation of a new trigger mechanism for the urgent procedure and the clarification of the transparency obligation of companies. The European regulation marks a significant step towards increased health security for Europeans, and we welcome that."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph